Unicycive Therapeutics, Inc.
UNCY
$6.93
-$0.19-2.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.86% | -46.73% | -165.42% | 102.72% | -176.03% |
| Total Depreciation and Amortization | 12.69% | 20.33% | 222.12% | -52.46% | 63.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.97% | 70.67% | 101.22% | -163.14% | 509.51% |
| Change in Net Operating Assets | -221.03% | 105.74% | -2,237.04% | -196.30% | 51.83% |
| Cash from Operations | -22.66% | 35.56% | -33.25% | -37.90% | -47.51% |
| Capital Expenditure | 100.00% | 91.67% | 70.00% | -166.67% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -54,768.18% | 91.67% | 70.00% | -166.67% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 897.22% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 35.53% | -419.11% | -221.83% | 94.34% | -55.12% |
| Cash from Financing | 1,709.86% | 16,871.97% | 1,454.38% | -94.43% | 278.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.52% | 315.92% | 135.78% | -116.25% | -33.61% |